JP2006265245A5 - - Google Patents

Download PDF

Info

Publication number
JP2006265245A5
JP2006265245A5 JP2006068066A JP2006068066A JP2006265245A5 JP 2006265245 A5 JP2006265245 A5 JP 2006265245A5 JP 2006068066 A JP2006068066 A JP 2006068066A JP 2006068066 A JP2006068066 A JP 2006068066A JP 2006265245 A5 JP2006265245 A5 JP 2006265245A5
Authority
JP
Japan
Prior art keywords
seq
antibody
acid sequence
amino acid
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006068066A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006265245A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2006265245A publication Critical patent/JP2006265245A/ja
Publication of JP2006265245A5 publication Critical patent/JP2006265245A5/ja
Withdrawn legal-status Critical Current

Links

JP2006068066A 2005-03-23 2006-03-13 癌の治療用の抗ｃｔｌａ４抗体及びインドリノンの組合せ療法 Withdrawn JP2006265245A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66465305P 2005-03-23 2005-03-23

Publications (2)

Publication Number Publication Date
JP2006265245A JP2006265245A (ja) 2006-10-05
JP2006265245A5 true JP2006265245A5 (https=) 2009-06-04

Family

ID=36680342

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006068066A Withdrawn JP2006265245A (ja) 2005-03-23 2006-03-13 癌の治療用の抗ｃｔｌａ４抗体及びインドリノンの組合せ療法

Country Status (16)

Country Link
US (1) US20090074787A1 (https=)
EP (1) EP1863532A1 (https=)
JP (1) JP2006265245A (https=)
KR (1) KR20070104673A (https=)
CN (1) CN101146553A (https=)
AR (1) AR054237A1 (https=)
AU (1) AU2006227880A1 (https=)
BR (1) BRPI0607579A2 (https=)
CA (1) CA2602316A1 (https=)
IL (1) IL185491A0 (https=)
MX (1) MX2007011767A (https=)
NZ (1) NZ561138A (https=)
RU (1) RU2007135167A (https=)
TW (1) TW200700083A (https=)
WO (1) WO2006101692A1 (https=)
ZA (1) ZA200708026B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101267824A (zh) * 2005-09-20 2008-09-17 辉瑞产品公司 使用酪氨酸激酶抑制剂的治疗剂型和方法
CA2647282A1 (en) * 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
EP2109455A2 (en) * 2006-12-27 2009-10-21 The Johns Hopkins University Compositions and methods for stimulating an immune response
WO2010014784A2 (en) * 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
SMT201700293T1 (it) * 2009-07-20 2017-07-18 Bristol Myers Squibb Co Combinazione di un anticorpo anti-ctla-4 con etoposide per il trattamento sinergico di malattie proliferative
CA2777226A1 (en) * 2009-10-12 2011-04-21 Pfizer Inc. Cancer treatment
CN107898791A (zh) 2010-06-03 2018-04-13 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
CA2828940C (en) 2011-03-10 2024-04-16 Provectus Pharmaceuticals, Inc. Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
AU2013255511B2 (en) 2012-05-04 2016-01-28 Pfizer Inc. Prostate-associated antigens and vaccine-based immunotherapy regimens
CN113967253A (zh) 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
WO2014182761A1 (en) * 2013-05-09 2014-11-13 Mayo Foundation For Medical Education And Research Treating patients based on immune subtypes
GB201413665D0 (en) 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
KR101940430B1 (ko) * 2014-08-07 2019-01-18 가꼬우호우징 효고 이카다이가쿠 Il-18과 분자 표적 항체를 병용하는 암 치료약
HRP20190881T1 (hr) 2014-08-28 2019-07-12 Halozyme, Inc. Kombinacijska terapija s hijaluronan-razgrađujućim enzimom i inhibitorom imunološke kontrolne točke
ES2753391T3 (es) 2014-10-14 2020-04-08 Halozyme Inc Composiciones de adenosina desaminasa 2 (ADA2), variantes de la misma y métodos de uso de las mismas
CN108271359B (zh) * 2015-02-13 2021-11-09 索伦托药业有限公司 结合ctla4的抗体治疗剂
WO2016161347A1 (en) * 2015-04-03 2016-10-06 Pharmacyclics Llc Combinations for generating tumor-specific immunological memory
KR20180015269A (ko) 2015-06-24 2018-02-12 이모듈런 테라퓨틱스 리미티드 암 치료에 사용하기 위한 체크포인트 저해제와 마이코박테리움 전체 세포
EP3347380B1 (en) 2015-09-11 2024-09-25 Nascent Biotech, Inc. Enhanced delivery of drugs to the brain
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
US11643463B2 (en) * 2017-05-19 2023-05-09 Wuxi Biologics (Shanghai) Co., Ltd. Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
WO2019148444A1 (en) * 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
IL277095B2 (en) * 2018-03-07 2025-10-01 Pfizer Preparations containing anti-PD-1 antibody
WO2020014543A2 (en) 2018-07-11 2020-01-16 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
BR112021012536A2 (pt) 2018-12-26 2021-09-14 City Of Hope Proteínas de ligação anti-ctla4 mascaradas ativáveis
KR102371980B1 (ko) 2020-06-29 2022-03-08 인하대학교 산학협력단 췌장암 예방 또는 치료용 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) * 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) * 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
JP2001523958A (ja) * 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
US7109003B2 (en) * 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6682736B1 (en) * 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
SI1255752T1 (sl) * 2000-02-15 2007-12-31 Pharmacia & Upjohn Co Llc S pirolom substituirani zaviralci 2-indolinon protein kinaza
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
AU2002303892A1 (en) * 2001-05-30 2002-12-09 Jingrong Cui 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
US6680306B2 (en) * 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
WO2004029069A2 (en) * 2002-09-30 2004-04-08 Pfizer Products Inc. Hybridomas producing high levels of human sequence antibody
AR042042A1 (es) * 2002-11-15 2005-06-08 Sugen Inc Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
EP1670785B1 (en) * 2003-10-02 2010-07-07 Pharmacia & Upjohn Company LLC Salts and polymorphs of a pyrrole-substituted indolinone compound
US20050182122A1 (en) * 2003-11-20 2005-08-18 Bello Carlo L. Method of treating abnormal cell growth using indolinone compounds
EP1732600A2 (en) * 2004-03-26 2006-12-20 Pfizer Products Incorporated Uses of anti-ctla-4 antibodies

Similar Documents

Publication Publication Date Title
JP2006265245A5 (https=)
RU2007135167A (ru) Комбинированная терапия с использованием анти-ctla4-антитела и индолинона для лечения рака
JP2023130496A (ja) 癌治療のための併用療法
EP3210627A1 (en) Conjugates of cell binding molecules with cytotoxic agents
JP2018537975A5 (https=)
JP2020502271A5 (https=)
JP2025013486A (ja) 放射性免疫複合体とｄｎａの損傷および修復阻害剤の併用療法
JP2019503349A5 (https=)
JP2019521087A5 (https=)
TW202019487A (zh) 抗體-藥物結合物及微管蛋白抑制劑之組合
JP2020510662A5 (https=)
JP2019501204A5 (https=)
JP2019503387A5 (https=)
JP2014533279A5 (https=)
JP2008546792A5 (https=)
JP2022189827A (ja) 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与
KR101993963B1 (ko) 항 종양제 및 항 종양 효과 증강제
WO2016204193A1 (ja) 抗がん剤
JP2013100314A5 (https=)
JP2022513684A5 (https=)
JP2015500822A5 (https=)
JP2021511372A5 (https=)
CN112826940A (zh) 细胞毒素分子同细胞结合受体分子的共轭体
JP2015517523A5 (https=)
JP2011505371A5 (https=)